AZN
AstraZeneca PLC
Stock
$156.90−0.80 (−0.51%)Close Oct 2, 2026
Cash flow statement
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.6B | $11.9B | $10.3B | $9.8B | $6.0B | $4.8B | $3.0B | $2.6B | $3.6B | $4.1B | $3.3B |
| Capital expenditures | $2.8B | $1.9B | $1.4B | $1.1B | $1.1B | $961M | $979M | $1.0B | $1.3B | $1.4B | $1.3B |
| Free cash flow | $11.8B | $9.9B | $9.0B | $8.7B | $4.9B | $3.8B | $2.0B | $1.6B | $2.3B | $2.7B | $2.0B |
| Stock-based compensation | $719M | $660M | $579M | $619M | $615M | $277M | $259M | $219M | $220M | $241M | $211M |
| Buybacks | $521M | $81M | — | — | $149M | — | — | — | — | — | — |
| Dividends paid | $5.0B | $4.6B | $4.5B | $4.4B | $3.9B | $3.6B | $3.6B | $3.5B | $3.5B | $3.6B | $3.5B |
| Dividends per share | $3.13 | $2.97 | $2.90 | $2.90 | $2.80 | $2.80 | — | — | — | — | — |
| Free cash flow margin | 20.0% | 18.4% | 19.6% | 19.7% | 13.0% | 14.4% | 8.2% | 7.1% | 10.0% | 11.7% | 8.1% |